...ThromboGenics N.V. (Euronext:THR) discontinued enrollment in the Phase II CIRCLE trial evaluating ocriplasmin (THR-409) to treat...
...microplasmin, a truncated form of the natural human protein plasmin. The product is marketed as Jetrea...
...Leuven, Belgium Product: Jetrea ocriplasmin (THR-409) (formerly Microplasmin) Business: Ophthalmic Molecular target: NA Description: Recombinant microplasmin...

...ThromboGenics amended the double-blind, sham-controlled, international Phase II CIRCLE trial of Jetrea to expand the enrollment...
...Leuven, Belgium Product: Jetrea ocriplasmin (THR-409) (formerly Microplasmin) Business: Ophthalmic Molecular target: NA Description: Recombinant microplasmin...
...patients with total PVD by month 3; safety Status: Phase II amended Milestone: NA Chris Lieu Jetrea ThromboGenics N.V. ocriplasmin THR-409...

...and 0.125 mg ocriplasmin in 230 patients with non-proliferative diabetic retinopathy. Ocriplasmin is approved as Jetrea...
...Belgium Product: Jetrea ocriplasmin (formerly Microplasmin ) Business: Ophthalmic Molecular target: Not applicable Description: Recombinant microplasmin...

...about 220 patients with symptomatic VMA showed that a single 125 ug intravitreal injection of Jetrea...
...Inc. ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) has ex-U.S. commercialization rights to Jetrea...
...Belgium Product: Jetrea ocriplasmin (formerly Microplasmin ) Business: Ophthalmic Molecular target: Not applicable Description: Recombinant microplasmin...

...ThromboGenics said Argentina and Israel approved Jetrea ocriplasmin to treat vitreomacular traction (VMT), including when associated...
...commercialization rights to the recombinant microplasmin, a truncated form of the natural human protein plasmin. Jetrea...
...to treat symptomatic vitreomacular adhesion (VMA). ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Product: Jetrea ocriplasmin (formerly Microplasmin...

...ThromboGenics said Australia's Therapeutic Goods Administration ( TGA ) approved Jetrea ocriplasmin to treat vitreomacular traction...
...commercialization rights to Jetrea and plans to launch the product in Australia by February 2015. Jetrea...
...of the natural human protein plasmin. ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Product: Jetrea ocriplasmin (formerly Microplasmin...

...ThromboGenics said South Korea approved Jetrea ocriplasmin to treat vitreomacular adhesion (VMA), including when associated with...
...will launch the test in Spain this month. Alcon has ex-U.S. commercialization rights to Jetrea. Jetrea...
...of the natural human protein plasmin. ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Product: Jetrea ocriplasmin (formerly Microplasmin...

...ThromboGenics said Uruguay and Singapore approved Jetrea ocriplasmin to treat vitreomacular traction (VMT), including when associated...
...Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) has ex-U.S. commercialization rights to Jetrea, which is recombinant microplasmin...
...in the U.S. of Jetrea. ThromboGenics N.V . (Euronext:THR), Leuven, Belgium Product: Jetrea ocriplasmin (formerly Microplasmin...

...Morgan Stanley as a result of a struggle to gain uptake in the U.S. of Jetrea...
...treat vitreomacular traction (VMT). ThromboGenics said it plans to pursue a U.S. commercial partner for Jetrea...

...result of a struggle to gain uptake in the U.S. of its sole marketed product, Jetrea...
...see BioCentury, March 3). ThromboGenics said it plans to pursue a U.S. commercial partner for Jetrea...
...ThromboGenics said it is currently in discussions with potential partners but declined to disclose details. Jetrea...